# Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-upcoming-presentation-of-phase-2-data-highlighting-the-potential-abscopal-effects-of-vp-315-in-the-treatment-of-basal-cell-carcinoma-at-the-2026-society-for-investigative-dermatology-sid-annual-meeting
Ticker: VRCA
Company: Verrica Pharmaceuticals
Source: Verrica Pharmaceuticals
Published: 2026-05-05 20:05 EST
Original Source URL: https://verrica.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-21 12:05 EST — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522) — Source: Verrica Pharmaceuticals
- 2026-06-22 12:05 EST — [Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal--f2e2423b) — Source: Verrica Pharmaceuticals
- 2026-05-28 12:05 EST — [Verrica to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/VRCA/verrica-to-participate-in-the-jefferies-global-healthcare-conference) — Source: Verrica Pharmaceuticals
- 2026-05-13 12:00 EST — [Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq) — Source: Verrica Pharmaceuticals
- 2026-05-12 20:01 EST — [Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2026-financial-results) — Source: Verrica Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)